These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31655359)

  • 1. DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial.
    Sundar R; Ng A; Zouridis H; Padmanabhan N; Sheng T; Zhang S; Lee MH; Ooi WF; Qamra A; Inam I; Hewitt LC; So JB; Koh V; Nankivell MG; Langley RE; Allum WH; Cunningham D; Rozen SG; Yong WP; Grabsch HI; Tan P
    Eur J Cancer; 2019 Dec; 123():48-57. PubMed ID: 31655359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma.
    Reece-Smith AM; Saunders JH; Soomro IN; Bowman CR; Duffy JP; Kaye PV; Welch NT; Madhusudan S; Parsons SL
    Ann R Coll Surg Engl; 2017 May; 99(5):378-384. PubMed ID: 28462649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy improves survival in patients with oesophageal mucinous adenocarcinoma: Post-hoc analysis of the UK MRC OE02 and OE05 trials.
    Liu DHW; Šefčovičová N; Emmerson J; Spaans LN; Saito Y; Hutchins G; Nankivell MG; Langley RE; Allum W; Cunningham D; Langer R; Grabsch HI
    Eur J Cancer; 2022 Jul; 170():140-148. PubMed ID: 35635935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial.
    Hale MD; Nankivell M; Hutchins GG; Stenning SP; Langley RE; Mueller W; West NP; Wright AI; Treanor D; Hewitt LC; Allum WH; Cunningham D; Hayden JD; Grabsch HI
    Oncotarget; 2016 Nov; 7(47):77565-77575. PubMed ID: 27769054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial.
    Davarzani N; Hutchins GGA; West NP; Hewitt LC; Nankivell M; Cunningham D; Allum WH; Smyth E; Valeri N; Langley RE; Grabsch HI
    Histopathology; 2018 Jun; 72(7):1180-1188. PubMed ID: 29465751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response.
    Schneider BJ; Shah MA; Klute K; Ocean A; Popa E; Altorki N; Lieberman M; Schreiner A; Yantiss R; Christos PJ; Palmer R; You D; Viale A; Kermani P; Scandura JM
    Clin Cancer Res; 2017 Jun; 23(11):2673-2680. PubMed ID: 27836862
    [No Abstract]   [Full Text] [Related]  

  • 7. Propensity score regression analysis of oesophageal adenocarcinoma treatment with surgery alone or neoadjuvant chemotherapy.
    Powell AGMT; Karran A; Blake P; Christian A; Roberts SA; Lewis WG
    BJS Open; 2020 Aug; 4(4):593-600. PubMed ID: 32374504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
    Ajani JA; Buyse M; Lichinitser M; Gorbunova V; Bodoky G; Douillard JY; Cascinu S; Heinemann V; Zaucha R; Carrato A; Ferry D; Moiseyenko V
    Eur J Cancer; 2013 Nov; 49(17):3616-24. PubMed ID: 23899532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
    Fareed KR; Ilyas M; Kaye PV; Soomro IN; Lobo DN; Parsons SL; Madhusudan S
    Histopathology; 2009 Oct; 55(4):399-406. PubMed ID: 19817890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
    Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
    Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
    Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
    Ott K; Rachakonda PS; Panzram B; Keller G; Lordick F; Becker K; Langer R; Buechler M; Hemminki K; Kumar R
    Ann Surg Oncol; 2011 Sep; 18(9):2688-98. PubMed ID: 21347786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
    Chau I; Norman AR; Cunningham D; Oates J; Hawkins R; Iveson T; Nicolson M; Harper P; Seymour M; Hickish T
    Ann Oncol; 2009 May; 20(5):885-91. PubMed ID: 19164454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel, Cisplatin, and 5-Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma.
    Fiteni F; Paget-Bailly S; Messager M; N'Guyen T; Lakkis Z; Mathieu P; Lamfichekh N; Picard A; Benzidane B; Cléau D; Bonnetain F; Borg C; Mariette C; Kim S
    Cancer Med; 2016 Nov; 5(11):3085-3093. PubMed ID: 27726290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma.
    Kim S; Paget-Bailly S; Messager M; Nguyen T; Mathieu P; Lamfichekh N; Fein F; Fratté S; Cléau D; Lakkis Z; Jary M; Sakek N; Jacquin M; Foubert A; Bonnetain F; Mariette C; Fiteni F; Borg C
    Eur J Surg Oncol; 2017 Jan; 43(1):218-225. PubMed ID: 27425578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.
    Noble F; Lloyd MA; Turkington R; Griffiths E; O'Donovan M; O'Neill JR; Mercer S; Parsons SL; Fitzgerald RC; Underwood TJ;
    Br J Surg; 2017 Dec; 104(13):1816-1828. PubMed ID: 28944954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma.
    Borg D; Larsson AH; Hedner C; Nodin B; Johnsson A; Jirström K
    J Transl Med; 2018 Oct; 16(1):290. PubMed ID: 30355278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic and potentially predictive value of the Laurén classification in oesophageal adenocarcinoma.
    van der Kaaij RT; Snaebjornsson P; Voncken FE; van Dieren JM; Jansen EP; Sikorska K; Cats A; van Sandick JW
    Eur J Cancer; 2017 May; 76():27-35. PubMed ID: 28262585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.